Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 08 2020
Historique:
received: 25 03 2020
revised: 10 05 2020
accepted: 12 05 2020
entrez: 12 7 2020
pubmed: 12 7 2020
medline: 8 9 2020
Statut: ppublish

Résumé

Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized infiltrative cardiomyopathy in which conduction system disease is common. The aim of our study was to define the incidence and prevalence of high-grade atrioventricular (AV) block requiring pacemaker implantation in our quaternary referral center. This was a single-center retrospective cohort study of 369 consecutive patients with ATTR-CA who underwent 12-lead electrocardiogram at the time of ATTR-CA diagnosis. During a mean follow-up of 28 months, serial ECGs and the electronic medical record were examined for the development of high-grade AV block and pacemaker implantation. Wild-type ATTR-CA (wtATTR-CA) was diagnosed in 261 patients and 108 had hereditary ATTR-CA (hATTR-CA). A total of 35 (9.5%) had high-grade AV block requiring pacemaker implantation at the time of diagnosis of ATTR-CA. The most common conduction abnormalities evident on the baseline ECG were a wide QRS complex, present in 51% with wtATTR-CA and 48% with hATTR-CA (p = 0.62), followed by first-degree AV block, which was present in 49% with wtATTR-CA and 43% with hATTR-CA (p = 0.31). During follow-up, high-grade AV block developed in 10% of those with hATTR-CA and 12% of patients with wtATTR-CA (p = 0.64). On multivariable models, high-grade AV block was not significantly associated with increased mortality. More advanced ATTR-CA stage and a history of obstructive coronary artery disease were associated with increased mortality on multivariable models. In conclusion, the incidence and prevalence of high-grade AV block is high in patients with ATTR-CA. Patients with ATTR-CA require close monitoring during follow-up for the development of conduction system disease.

Identifiants

pubmed: 32650908
pii: S0002-9149(20)30497-5
doi: 10.1016/j.amjcard.2020.05.021
pii:
doi:

Substances chimiques

Prealbumin 0
TTR protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

140-146

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Eoin Donnellan (E)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Oussama M Wazni (OM)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Walid I Saliba (WI)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Mazen Hanna (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Mohamed Kanj (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Divyang R Patel (DR)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Bryan Wilner (B)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Arshneel Kochar (A)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Wael A Jaber (WA)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Electronic address: jaberw@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH